The following article requires a subscription:



(Format: HTML, PDF)

We review the latest literature on the neuropharmacological treatments for acquired nystagmus. Nystagmus may have a significantly impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.

(C) 2012 BMJ Publishing Group Ltd